Quebec pharmacies report widespread shortages of generic semaglutide, the active ingredient in Ozempic, as demand outpaces supply, according to pharmacists and provincial health authorities. The drug, used to manage type 2 diabetes and obesity, faces supply chain disruptions amid rising patient demand and manufacturing constraints.
Why the Shortage Matters to Patients and Healthcare Systems
Shortages of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, threaten access for patients relying on the medication to regulate blood sugar and achieve weight loss. In Quebec, where the drug has gained popularity for its dual therapeutic applications, pharmacists report that 60% of generic semaglutide prescriptions cannot be fulfilled, according to a June 2026 survey by the Quebec Pharmacists’ Association. This aligns with broader trends in North America, where Ozempic and Wegovy (its higher-dose counterpart) have seen a 400% increase in prescriptions since 2021, per the U.S. Food and Drug Administration (FDA).
In Plain English: The Clinical Takeaway
- Semaglutide works by mimicking a hormone that regulates appetite and blood sugar, reducing hunger and improving glucose control.
- Shortages arise from increased demand, production delays, and limited generic manufacturing capacity.
- Patients should consult healthcare providers for alternative treatments or dose adjustments if their medication is unavailable.
How Semaglutide Works and Its Clinical Efficacy
Semaglutide belongs to a class of drugs known as GLP-1 receptor agonists, which stimulate insulin release and suppress glucagon secretion in response to food intake. Its mechanism of action involves binding to GLP-1 receptors in the pancreas, brain, and gastrointestinal tract, thereby reducing appetite and slowing gastric emptying. Clinical trials, including the Semaglutide Trial in Participants with Obesity (STEP) series, demonstrated that semaglutide led to an average 15% weight loss in participants over 68 weeks, with 80% achieving at least 5% weight reduction.
The shortage coincides with the drug’s expanded use beyond its original indication for type 2 diabetes. In 2021, the FDA approved semaglutide for chronic weight management, sparking a surge in prescriptions. However, manufacturing bottlenecks—such as delays in active pharmaceutical ingredient (API) production—have exacerbated supply issues. Novo Nordisk, the drug’s manufacturer, reported that generic producers face challenges replicating the drug’s complex formulation, which requires precise controlled-release technology.
Geoeconomic and Regulatory Implications
The Quebec shortage reflects broader challenges in global pharmaceutical supply chains. In the U.S., the FDA has not reported widespread shortages of semaglutide but has issued guidance for healthcare providers to manage patient expectations. The European Medicines Agency (EMA) has also noted localized shortages, particularly in countries with high prescription rates. In contrast, the United Kingdom’s National Health Service (NHS) has implemented stricter prescribing criteria to prioritize patients with the highest clinical need.
Funding transparency reveals that the STEP trials, which underpin semaglutide’s regulatory approvals, were supported by Novo Nordisk. While independent studies have corroborated the drug’s efficacy, critics argue that industry-funded research may overstate benefits and underreport adverse events. A 2023 meta-analysis in *The Lancet* found that semaglutide’s side effects—including nausea, vomiting, and diarrhea—occur in 30–40% of patients, though most resolve within the first few weeks of treatment.
Contraindications & When to Consult a Doctor
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. It should also be avoided in individuals with a history of pancreatitis, as the drug may increase the risk of this condition. Patients experiencing severe abdominal pain, persistent vomiting, or signs of an allergic reaction (e.g., swelling, difficulty breathing) should seek immediate medical attention.
For those unable
